4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-ylboronic acid | 1015242-58-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-ylboronic acid
• 英文别名: (4-methyl-3,4-dihydro-2H-1,4-benzooxaazin-6-yl)boronic acid；(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)boronic acid；4-Methyl-2,3-dihydro-1,4-benzoxazine-6-boronic acid；(4-methyl-2,3-dihydro-1,4-benzoxazin-6-yl)boronic acid
• CAS: 1015242-58-6
• 化学式: C₉H₁₂BNO₃
• 分子量: 193.01
• InChiKey: CKKPNGSUPGAEOV-UHFFFAOYSA-N

物化性质

• 沸点：
  404.0±55.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.81
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 4-chloro-5-[(1S)-2-methoxy-1-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-3,6-dimethylpyridine-2-carboxylate 、 4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-ylboronic acid 在 二(三叔丁基膦)钯 、 potassium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs

  摘要：

  Optimization of pyridine-based noncatalytic site integrase inhibitors (NCINIs) based on compound 2 has led to the discovery of molecules capable of inhibiting virus harboring N124 variants of HIV integrase (IN) while maintaining minimal contribution of enterohepatic recirculation to clearance in rat. Structure activity relationships at the C6 position established chemical space where the extent of enterohepatic recirculation in the rat is minimized. Desymmetrization of the C4 substituent allowed for potency optimization against virus having the N124 variant of integrase. Combination of these lessons led to the discovery of compound 20, having balanced serum-shifted antiviral potency and minimized excretion in to the biliary tract in rat, potentially representing a clinically viable starting point for a new treatment option for individuals infected with HIV.

  DOI：

  10.1021/acsmedchemlett.6b00194

文献信息

• SUBSTITUTED IMIDAZO-BASED COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3
  申请人：[en]CELGENE CORPORATION

  公开号：WO2024137743A1

  公开（公告）日：2024-06-27

  Provided herein are compounds and compositions thereof for modulating IRAK3. In some embodiments, the compounds and compositions are provided for treatment of cancer.